Pages that link to "Q30307291"
Jump to navigation
Jump to search
The following pages link to Src family kinases and HER2 interactions in human breast cancer cell growth and survival (Q30307291):
Displaying 50 items.
- p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2 (Q24294568) (← links)
- Identification of a Src kinase SH3 binding site in the C-terminal domain of the human ErbB2 receptor tyrosine kinase (Q24297527) (← links)
- Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor (Q24301556) (← links)
- Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation (Q24306910) (← links)
- Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells (Q24309725) (← links)
- Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk. (Q24522667) (← links)
- SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells (Q24656966) (← links)
- Differential regulation of EphA2 in normal and malignant cells (Q24684095) (← links)
- Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells (Q24796859) (← links)
- Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (Q27851586) (← links)
- MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90 (Q28271920) (← links)
- HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer (Q28476604) (← links)
- The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation (Q28545814) (← links)
- Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma (Q30411769) (← links)
- Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models (Q30412086) (← links)
- Functional interactions between Choline kinase α, epidermal growth factor receptor and c-Src in breast cancer cell proliferation (Q30424954) (← links)
- Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells (Q30439082) (← links)
- Pathways to tamoxifen resistance (Q30441001) (← links)
- c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function (Q30442374) (← links)
- Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells (Q30486408) (← links)
- Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling (Q33553538) (← links)
- Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression (Q33688434) (← links)
- Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer (Q33737058) (← links)
- Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines (Q33822560) (← links)
- DHHC20: a human palmitoyl acyltransferase that causes cellular transformation (Q33946275) (← links)
- Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis (Q33997021) (← links)
- Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data (Q34182834) (← links)
- Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents (Q34440814) (← links)
- p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. (Q34472383) (← links)
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (Q34493341) (← links)
- Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents (Q35040797) (← links)
- SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment (Q35113027) (← links)
- FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells (Q35191084) (← links)
- A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells (Q35351845) (← links)
- Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. (Q35479665) (← links)
- Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies (Q35573116) (← links)
- Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors (Q35609713) (← links)
- Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity (Q35641650) (← links)
- Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer (Q35868817) (← links)
- The interplay between Src family kinases and receptor tyrosine kinases (Q35920901) (← links)
- Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation (Q36034029) (← links)
- ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. (Q36210983) (← links)
- Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines (Q36457506) (← links)
- Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity (Q36612010) (← links)
- Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors. (Q36864805) (← links)
- Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi (Q36932170) (← links)
- Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer (Q37290504) (← links)
- Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. (Q37384464) (← links)
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways (Q37425090) (← links)
- EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. (Q37552436) (← links)